Objective — to study the clinical value of the new molecular markers ERG, p27, and Ki-67 in predicting the course of localized prostate cancer (PC). Material and methods. Forty-four patients with localized PC (Т2N0M0) who had not received neoadjuvant hormone therapy were selected from 208 patients who had undergone radical prostatectomy. Serum PSA levels were monitored every 3 months postsurgery. A study group included 16 patients with biochemically verified recurrent PC; a control group comprised 28 patients without signs of recurrence. Intraoperative samples from all the patients were immunohistologically examined to estimate ERG, p27, and Ki-67 expression levels. Results. A positive ERG expression was detected in 20 patients and encountered with equal frequency in both groups: in 7 (48.8%) patients in the study group and 13 (46.4%) patients in the control group. No p27 expression was noted in 4 (25.0%) patients with a biochemical recurrence and in 6 (21.4%) without recurrence. The similar results were obtained when comparing the patients with a mild or moderate positive response: 5 (31.3%) patients in the study group and 8 (28.6%) patients in the control group. High p27+++ expression was seen 3 times less frequently in the study group than that in the control group: in 2 (12.5%) and 6 (21.4%). In the biochemical recurrence group, Ki-67 expression was in the range from 2.40 to 27.12, averaging 11.46±1.57; in the non-recurrence group, this was 4.17—17.83, averaging 8.36±0.73. Conclusion. The use of ERG and p27 as highly specific prognostic markers for PC is questionable; they call for further, more detailed investigation. The pronounced positive p27 response may be indicative of the favorable course of the disease. Ki-67 expression, along with PSA level and Gleason grade, is a valid independent prognostic factor for recurrence.